|
Aug 1
|
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
|
|
Jul 31
|
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
|
|
Jul 24
|
TSX Growth Companies With High Insider Ownership For July 2025
|
|
Jul 18
|
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
|
|
Jun 25
|
3 TSX Growth Companies With Insider Ownership As High As 22%
|
|
Sep 27
|
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
|
|
Jan 4
|
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
|
|
Dec 19
|
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
|
|
Nov 2
|
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
|
|
Aug 27
|
Individual investors account for 43% of Knight Therapeutics Inc.'s (TSE:GUD) ownership, while private companies account for 22%
|